sur ABIVAX (EPA:ABVX)
Abivax strengthens its team and announces its financial results for H1 2026
Abivax has unveiled its latest financial results for the first half of 2026. The company has €402.4 million in cash, figures increased by a €767.1 million fundraising in July, guaranteeing its financial strength until the end of 2029.
Two strategic appointments have been announced. Chris Rabbat becomes Chief Medical Officer, succeeding Fabio Cataldi, and will bring his expertise in inflammatory diseases. Tim Kelly is appointed Chief Technology Officer, to enhance the company's commercial and technological output.
The repurchase of the Royalties Certificates significantly reduced future liabilities, resulting in a charge of €43.2 million. R&D expenditures increased, particularly concerning obefazimod. Abivax is preparing for the potential commercialization of this treatment.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX